Centre for Nanotechnology & Regenerative Medicine, UCL Division of Surgery & Interventional Science, University College London (UCL), London NW3 2QG, UK.
J Biotechnol. 2013 Mar 10;164(1):151-70. doi: 10.1016/j.jbiotec.2013.01.020. Epub 2013 Jan 30.
Percutaneous coronary intervention (PCI) is used to treat blocked coronary arteries. Bare-metal stents (BMS) were first used in PCI but often necessitated repair procedures due to in-stent restenosis. Drug-eluting stents (DES) were developed to address this problem as the stent-incorporated anti-proliferative drugs prevented restenosis. However late-stent thrombosis arose with the use of DES due to polymer hypersensitivity and impaired re-endothelialization. Evidence suggests that using a combination of biofunctionalized polymers and antibody/peptide motifs can prevent thrombosis while ensuring in situ endothelialization. The advent of nanotechnology has engendered techniques like layer-by-layer self-assembly, and localized drug and gene delivery using nanoparticles. Therefore, this review seeks to explore the convergence of biotechnology and nanotechnology for the next generation coronary stent coatings, with an emphasis on its development from bench to beside.
经皮冠状动脉介入治疗（PCI）用于治疗阻塞的冠状动脉。最初在 PCI 中使用了裸金属支架（BMS），但由于支架内再狭窄，通常需要进行修复手术。药物洗脱支架（DES）的开发是为了解决这个问题，因为支架中包含的抗增殖药物可以预防再狭窄。然而，由于聚合物过敏和内皮化受损，DES 的使用导致晚期支架血栓形成。有证据表明，使用结合了生物功能化聚合物和抗体/肽基序的组合可以预防血栓形成，同时确保原位内皮化。纳米技术的出现带来了层状自组装等技术，以及使用纳米颗粒进行局部药物和基因递送。因此，本综述旨在探讨生物技术和纳米技术在下一代冠状动脉支架涂层中的融合，重点关注其从实验室到临床的发展。
Zotero 插件